Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACT 001

Next Previous
Drug Profile

ACT 001

Alternative Names: ACT-001

Latest Information Update: 04 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Accendatech
  • Class Antineoplastics; Lactones; Sesquiterpenes; Small molecules
  • Mechanism of Action NF-kappa B inhibitors; STAT3 transcription factor inhibitors; Thyroid hormone binding protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain metastases; Interstitial lung diseases
  • Phase I/II Glioblastoma
  • No development reported Solid tumours

Most Recent Events

  • 25 Mar 2025 Accendatech in collaboration with National Neuroscience Institute plans a phase II trial for GLioblastoma (Recurrent, Second-line therapy or greater) in Singapore (PO) in April 2025 (NCT06894225)
  • 24 Feb 2025 Nationwide Children's Hospital plans a phase II trial for Glioma (Recurrent, In children, In adults, In adolescents, In infants) in Australia, Canada, Germany and USA (PO) in July 2025 (NCT06838676)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top